UMoleac ubhengeze ukukhululwa kweziphumo zokufunda ze-ATHENE, ezipapashwe kwi-Journal ye-American Medical Director Association (JAMDA).
Unyango olunokuthi lucothise ngokufanelekileyo ikhondo le-AD nje ukuba lufikelele kwinqanaba lonyango, luhlala luyimfuneko yonyango olungafezekiswanga. I-NeuroAiD™II ibonise ukuba ineempembelelo zokumodareyitha kwi-amyloid precursor protein (APP) processing2 kunye nokuguqulwa kweprotheyini ye-tau ibe yi-phosphorylated engaqhelekanga kunye neefom3 ezidibeneyo, kunye ne-neuro-regenerative kunye ne-neuro-restorative properties4. Iziphumo eziluncedo ze-NeuroAiD™II kwimisebenzi yengqondo engasebenzi kakuhle sele ibonisiwe kukwenzakala kwengqondo okubuhlungu5.
UNyango lwesifo se-Alzheimer nge-NEuoaid (ATHENE) Uphononongo luphononongo lokuqala lokuhlola ukhuseleko kunye nokusebenza kakuhle kwe-NeuroAiD™II kwizigulana ze-AD ezithambileyo nezizinzileyo kunyango oluqhelekileyo lweempawu.
I-ATHENE yayiyinyanga ye-6 i-randomized double-blind-blind, isilingo esilawulwa yi-placebo esilandelwa yi-label evulekile yokwandiswa kwe-NeuroAiD™II unyango lwezinye iinyanga ze-6. Izifundo ze-125 ezivela eSingapore zifakwe kulingo, oluququzelelwe yiMemory Aging and Cognition Centre, iNkqubo yezeMpilo yeYunivesithi yeSizwe, iNational Neuroscience Institute, kunye neSibhedlele saseSt Luke, eSingapore.
• I-NeuroAiD™ II ibonise ukhuseleko lwexesha elide njengonyango olongezelelweyo kwi-AD ngaphandle kokwanda kwezigulane ezifumana iziganeko ezimbi kakhulu okanye iziganeko ezimbi.
• Ukuqaliswa kwangethuba kwe-NeuroAiD™II kubonelele ngokuphuculwa kwexesha elide lokuqonda xa kuthelekiswa ne-placebo (iqela lokuqala kade) elilinganiswe yi-ADAS-cog, ngokwezibalo ezibalulekileyo kwiinyanga ze-9, kunye nokunciphisa ukuhla kwexesha.
Iziphumo zophando ze-ATHENE zixhasa inzuzo ye-NeuroAiD™II njengonyango olongezelelweyo olukhuselekileyo kunyango oluqhelekileyo lwe-AD njengoko uphando alufumananga ubungqina bokunyuka okukhulu kwiziganeko ezimbi phakathi kwe-MLC901 kunye ne-placebo. Uhlalutyo lucebisa ukubanakho kwe-MLC901 ekwehliseni isantya sokuqhubekela phambili kwe-AD ehambelanayo nezifundo zangaphambili ezipapashiweyo zeklinikhi kunye nezonyango, oko kuyenza ibe lunyango oluthembisayo kwizigulana ze-AD. Ezi ziphumo zifuna ukuqinisekiswa ngakumbi kwizifundo ezinkulu kunye nezide.
Ilizwi elivela kuMphandi oyiNtloko
“Isifo sika-Alzheimer ngoyena nobangela wesifo sengqondo esiyingozi, esibalelwa kuma-60-80 ekhulwini ngalinye. Kuze kube yimvume yamva nje ye-aducanumab yi-FDA, kwakungekho unyango lokuguqula isifo kwi-Alzheimer's Disease, kwaye unyango olukhoyo ngoku olukhoyo lufuna ukulibazisa okwethutyana ukwehla kweempawu ze-dementia kunye nokuphucula umgangatho wobomi kwabo bane-Alzheimer kunye nabanonopheli babo. Ke ngoko, kukho imfuneko yokubonelela abaguli kunye nabo babanonophelayo ukufikelela kwangethuba kuxilongo kunye nonyango olunoveli.
Iziphumo ezithembisayo zophononongo lwe-ATHENE kufuneka ziqondwe njengenxalenye ye-Alzheimer's Disease pipeline yokuphuhliswa kweziyobisi ukusuka kwi-symptomatic ukuya kunyango lokuguqula izifo. Olu phononongo kunye nolunye unyango olunokubakho kufuneka luvavanywe ngokungqongqo ngolingo lwezonyango oluyilwe kakuhle. "
UNjingalwazi uChristopher Chen
UMlawuli, i-Memory Aging and Cognition Centre, iNkqubo yezeMpilo yeYunivesithi yeSizwe kunye noNjingalwazi oDityanisiweyo, iSebe le-Pharmacology, i-Yong Loo Lin School of Medicine, iYunivesithi yeSizwe yaseSingapore.